Twist Bioscience Corporation
NASDAQ:TWSTMedical - Diagnostics & Research
+$2.15 today
- Market cap
- $7.66B
- Beta
- 2.21
- P/E (TTM)
- -64.5
- EPS (TTM)
- -$1.32
Volume 2.23M
Average 1.53M
TWST Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Twist Bioscience CorporationNASDAQ: TWST
Net Income · Q4 FY2026 · quarter ended Sep 2026
Net income dips below year-ago levels
Q4 FY2026 net income of $20.62M (cash outflow) fell 24.0% year over year, behind the +67.6% change in trailing-twelve-month net income. Sequentially, it fell 41.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Net income amounted to 28.3% of revenue in FY2026, up 7.7 pp from a year earlier.
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 8 analysts of -$85.27M (-34.5%) for the fiscal year ending Sep 2027, a slowdown from the +67.6% reported in FY2026.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- -$20.62M-41.2% QoQ
- Last fiscal yearSep 2026
- -$130.2M+67.6% YoY
- LTMSep 2026
- -$130.2M+67.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -24.0% | -25.6% | -1.6 pp |
| 1 year | +67.6% | -34.5% | -102.1 pp |
| 3-year CAGR | -14.0% | -68.5% | -54.5 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2026
- (130.2M) USD
- Year-over-year change
- -67.6%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2026 | 2026-09-30 | (130.2M) | -67.6% |
| FY2025 | 2025-09-30 | (77.67M) | +62.8% |
| FY2024 | 2024-09-30 | (208.73M) | -2.0% |
| FY2023 | 2023-09-30 | (204.62M) | +6.1% |
| FY2022 | 2022-09-30 | (217.86M) | — |
Net Income vs competitors
How TWST compares with its peers on the latest reported figures
- TWST's LTM Sep 2026 net income of $130.2M is the largest of the 2 companies compared; the peer median is $41.54M.
- Its year-over-year change of +67.6% is the lowest of 2, against a peer median of +400.4%.
- Net income amounts to 28.3% of revenue for TWST, versus a peer median of 5.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $130.2M | +67.6% | -14.0% | 28.3% | |
| LTM Jun 2026 | $41.54M | +400.4% | -35.9% | 5.3% | |
| Peer median (excluding TWST) | $41.54M | +400.4% | -35.9% | 5.3% | |
Competitors are the stored peer set for TWST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 | FY2026 Sep 2026 |
|---|---|---|---|---|---|
| Net Income | (217.86M) | (204.62M) | (208.73M) | (77.67M) | (130.2M) |
| Depreciation & Amortization | 16.51M | 29.31M | 31.43M | 24.85M | 26.48M |
| Deferred Income Tax | 0 | (410K) | 0 | 0 | 0 |
| Stock-Based Compensation | 79.66M | 30.28M | 50.93M | 64.46M | 69.86M |
| Change in Working Capital | (5.36M) | (1.01M) | 15.41M | (12.61M) | (7.83M) |
| Accounts Receivables | (9.62M) | (4.32M) | 8.44M | (22.38M) | (13.8M) |
| Inventory | (7.54M) | 7.24M | 7.99M | (4.23M) | (18.1M) |
| Accounts Payables | 7.38M | (2.51M) | (11.81M) | 9.33M | 13.93M |
| Other Working Capital | 4.42M | (1.42M) | 10.79M | 4.67M | 10.14M |
| Other Non-Cash Items | 2.66M | 3.98M | 46.86M | (46.66M) | 265K |
| Operating Cash Flow | (124.39M) | (142.47M) | (64.09M) | (47.63M) | (41.43M) |
| Capital Expenditures | (101.86M) | (27.78M) | (5.08M) | (28M) | (47.58M) |
| Acquisitions (Net) | (8.16M) | 5.86M | 0 | 2.5M | 0 |
| Purchases of Investments | (217.64M) | (76.35M) | (51.91M) | (49.39M) | (47.9M) |
| Sales of Investments | 100.48M | 154.74M | 53.91M | 50.14M | 49.35M |
| Other Investing Activities | (5.76M) | (5.86M) | 0 | 0 | (6.95M) |
| Investing Cash Flow | (232.93M) | 50.61M | (3.07M) | (24.76M) | (53.09M) |
| Debt Repayment | (1.56M) | 0 | 0 | 0 | 0 |
| Common Stock Issued | 269.82M | 0 | 0 | 13.56M | 446.72M |
| Common Stock Repurchased | (7.75M) | (4.41M) | (3.98M) | (16K) | (42K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 10.02M | 5.32M | 10.87M | 15M | 0 |
| Financing Cash Flow | 270.53M | 911K | 6.89M | 28.54M | 446.68M |
| Effect of Forex Changes | (319K) | (27K) | 126K | 583K | 24K |
| Net Change in Cash | (87.1M) | (90.98M) | (60.15M) | (43.27M) | 352.18M |
| Free Cash Flow | (226.24M) | (170.25M) | (69.17M) | (75.63M) | (89.01M) |
Twist Bioscience Corporation
NASDAQ:TWST
Intrinsic Alpha fair value
Locked
Current Price
$116.35
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.